InotivNOTVQ -9.91% EBITDA Margin % is -4.76% as of Mar. 2026. The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Inotiv ranks worse than 54.41% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Inotiv's EBITDA for the
three
months ended in Mar. 2026 was $-5.6 Mil. Inotiv's Revenue for the
three
months ended in Mar. 2026 was $117.7 Mil. Therefore, Inotiv's EBITDA margin for the quarter that ended in Mar. 2026 was -4.76%.
Inotiv (OTCPK:NOTVQ) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Inotiv EBITDA Margin % Related Terms
Inotiv EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Inotiv's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NOTVQ vs NDRA, XWEL, ADVB: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Inotiv's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inotiv EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Inotiv's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inotiv (NOTVQ) has a EBITDA Margin % of -4.76% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Inotiv and its competitors. According to the industry distribution chart, Inotiv ranks #111 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 54.4%.
Is Inotiv's EBITDA Margin % too high?
Inotiv's current EBITDA Margin % is -4.76%. Based on the distribution chart, Inotiv ranks #111 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does Inotiv's EBITDA Margin % compare to NDRA and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Inotiv ranks #111 out of 204 companies for EBITDA Margin %. This places Inotiv in the lower half of its industry. The industry median EBITDA Margin % is 5.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Inotiv and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inotiv's current EBITDA Margin % is -4.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inotiv stock overvalued right now?
Based on GuruFocus' analysis, Inotiv (NOTVQ) is currently considered Possible Value Trap. The stock's GF Value™ is $1.68, compared to a current price of $0.01 — trading 99.4% below its estimated fair value. The current EBITDA Margin % is -4.76%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Inotiv (NOTVQ), the current EBITDA Margin % is -4.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NOTVQ has been successfully added to your 